Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 263

Results For "US"

8889 News Found

Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India
News | January 21, 2026

Max Institute partners with Intuitive Surgical to expand robotic-assisted surgery in India

The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures


AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing
News | January 21, 2026

AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing

The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange


Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
News | January 21, 2026

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026


Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries
News | January 21, 2026

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally


Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
News | January 21, 2026

Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%

In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.


FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
Drug Approval | January 21, 2026

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells


Kindeva appoints David Stevens as new CEO
People | January 20, 2026

Kindeva appoints David Stevens as new CEO

Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors


AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder
Biotech | January 20, 2026

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector